Investor focus is currently bifurcated between a potential FDA bucillamine approval, and RVV’s ambitions and partnerships in the shroom space….
RVV.C
The collaboration will “accelerate the development of psilocybin in the treatment of cancer and the discovery of novel uses of undisclosed psychedelic compounds”….
One of the unfortunate downsides of living in the 21st century is the fact that most of us will have to deal with cancer in our lifetimes. The numbers…
Revive Therapeutics (RVV.C) is bouncing from a very significant support zone. Don’t believe me? Look at how price reacted in the past. This is the fourth time price has…
On November 11, 2020 Revive Therapeutics (RVV.C) Revive Therapeutics updated shareholders on its oral thin-film delivery system with psilocybin being developed “under a research partnership agreement with Reed Research…
Earlier this year, when Revive Therapeutics (RVV.C) announced they had some pharma IP that may be relevant to the treatment of COVID-19, plenty of folks laughed uproariously at the…
Revive Therapeutics (RVV.C) recent supply agreement with HAVN Life Sciences (HAVN.C) will give them a steady supply of naturally derived psychedelic compounds, like psilocybin, to be used in any…
Given the grim human and financial data, it’s no surprise that biotech companies and their shareholders are focused on developing coronavirus solutions….
Hey investors, interesting day to be an Asset Allocator as the market gives back gains, the marginal opinion by investors today was to give away the USA and American…
Normally when we we write about Revive Therapeutics (RVV.C), it’s generally to provide an update on their progress regarding their experimental COVID-19 palliative, Bucillamine. This update isn’t that, and…